计算溶液所需的质量、体积或浓度。
提供 ≥99% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
STL1267 is a potent and cross-the-blood-brain barrier REV-ERB agonist with a K i value of 0.16 µM for REV-ERBα. STL1267 shows no cytotoxicity. STL1267 inhibits the gene expression of BMAL1
In Vitro
STL1267 (5 µM; 24 h) decreases the expression of BMAL1 and increases the gene expression of Mtnd1, Mtco1, Vicad, Lcad, Scad, Lkb1, Sirt1, Nampt, Ppargc1a in HepG2 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: HepG2, C2C12 cells Concentration: 0-20 µM Incubation Time: 24 h Result: Showed no adverse effects on cell viability up to the maximum dose examined 20 µM. RT-PCRCell Line: HepG2 cells Concentration: 5 µM Incubation Time: 24 h Result: Decreased the gene expression of BMAL1, increased the gene expression of Mtnd1, Mtco1, Vicad, Lcad, Scad, Lkb1, Sirt1, Nampt, Ppargc1a.
In Vivo
STL1267 (50 mg/kg; i.p.; once) inhibits Bmal1 expression in mouse . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6-8 weeks, male C57Bl/6 J mice Dosage: 50 mg/kg Administration: I.p.; once Result: Showed a plasma half-life of 1.6 h, effectively suppressed BMAL1 expression in the liver at 12 h post-administration.
Form:Solid
IC50& Target:K i : 0.16 µM (REV-ERBα)